Table 1.
Summary of treatment compliance across the two 3-month placebo-controlled studies (114117/114418; ITT population)
| Compliance | Placebo, n (%) N=321 | UMEC 62.5 mcg, n (%) N=89 | UMEC 125 mcg, n (%) N=91 | VI 25 mcg, n (%) N=140 | UMEC/VI 62.5/25 mcg, n (%) N=282 | UMEC/VI 125/25 mcg, n (%) N=272 |
|---|---|---|---|---|---|---|
| n | 315 | 89 | 88 | 135 | 275 | 265 |
| <80 | 2 (<1) | 1 (1) | 1 (1) | 1 (<1) | 1 (<1) | 2 (<1) |
| ≥80 to <95 | 32 (10) | 9 (10) | 4 (5) | 11 (8) | 25 (9) | 27 (10) |
| ≥95 to ≤105 | 268 (85) | 75 (84) | 79 (90) | 115 (85) | 243 (88) | 229 (86) |
| >105 to ≤120 | 11 (3) | 2 (2) | 3 (3) | 6 (4) | 5 (2) | 6 (2) |
| >120 | 2 (<1) | 2 (2) | 1 (1) | 2 (1) | 1 (<1) | 1 (<1) |
Notes: N is the number of patients in the ITT population; n is the number of patients with analyzable data. Compliance data were accessed separately in each treatment period.
Abbreviations: ITT, intent-to-treat; UMEC, umeclidinium bromide; VI, vilanterol.